Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Drug Resistance

  Free Subscription

Articles published in Int J Antimicrob Agents

Retrieve available abstracts of 139 articles:
HTML format

Single Articles

    November 2022
  1. WOHLFARTH E, Kresken M, Higgins PG, Stefanik D, et al
    The evolution of carbapenem resistance determinants and major epidemiological lineages among carbapenem-resistant Acinetobacter baumannii isolates in Germany, 2010-2019.
    Int J Antimicrob Agents. 2022 Nov 11:106689.
    PubMed     Abstract available

    October 2022
  2. HUANG YS, Sun HY, Chang SY, Chuang YC, et al
    Virological Responses to Tenofovir Alafenamide-Containing Antiretroviral Therapy in People Living with HIV Who Had Lamivudine-Resistant and Lamivudine-Susceptible Hepatitis B Virus Coinfection.
    Int J Antimicrob Agents. 2022 Oct 21:106682.
    PubMed     Abstract available

  3. TANG R, Luo R, Tang S, Song H, et al
    Machine learning in predicting antimicrobial resistance: a systematic review and meta-analysis.
    Int J Antimicrob Agents. 2022 Oct 21:106684.
    PubMed     Abstract available

  4. LEE YL, Ko WC, Hsueh PR
    Geographic patterns of global isolates of carbapenem-resistant Klebsiella pneumoniae and the activity of ceftazidime/avibactam, meropenem/vaborbactam, and comparators against these isolates: Results from the Antimicrobial Testing Leadership and Survei
    Int J Antimicrob Agents. 2022 Oct 11:106679.
    PubMed     Abstract available

  5. ANTONELLI A, Coppi M, Tellapragada C, Hasan B, et al
    Isothermal microcalorimetry vs checkerboard assay to evaluate in-vitro synergism of meropenem-amikacin and meropenem-colistin combinations against multi-drug-resistant Gram-negative pathogens.
    Int J Antimicrob Agents. 2022;60:106668.
    PubMed     Abstract available

  6. PHUADRAKSA T, Wichit S, Arikit S, Songtawee N, et al
    Co-occurrence of mcr-2 and mcr-3 genes on chromosome of multidrug-resistant Escherichia coli isolated from healthy individuals in Thailand.
    Int J Antimicrob Agents. 2022;60:106662.
    PubMed     Abstract available

  7. GYSIN M, Hon PY, Tan P, Sengduangphachanh A, et al
    Apramycin susceptibility of multidrug-resistant Gram-negative blood culture isolates in five countries in Southeast Asia.
    Int J Antimicrob Agents. 2022;60:106659.
    PubMed     Abstract available

  8. LAN P, Lu Y, Jiang Y, Wu X, et al
    Catecholate siderophore receptor CirA impacts cefiderocol susceptibility in Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2022;60:106646.
    PubMed     Abstract available

  9. ZHOU H, Wang S, Wu Y, Dong N, et al
    Carriage of the mcr-9 and mcr-10 genes in clinical strains of the Enterobacter cloacae complex in China: a prevalence and molecular epidemiology study.
    Int J Antimicrob Agents. 2022;60:106645.
    PubMed     Abstract available

    September 2022
  10. LU Y, Liu JH, Yue C, Bergen PJ, et al
    Overexpression of mcr-1 disrupts cell envelope synthesis and causes the dysregulation of carbon metabolism, redox balance and nucleic acids.
    Int J Antimicrob Agents. 2022;60:106643.
    PubMed     Abstract available

  11. STELLA G, Volpicelli L, Carlo DD, Vicenti I, et al
    Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIV.
    Int J Antimicrob Agents. 2022;60:106636.
    PubMed     Abstract available

  12. KANJ SS, Bassetti M, Kiratisin P, Rodrigues C, et al
    Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections.
    Int J Antimicrob Agents. 2022;60:106633.
    PubMed     Abstract available

    August 2022
  13. SIMITSOPOULOU M, Kadiltzoglou P, Antachopoulos C, Roilides E, et al
    Daptomycin exerts differential immunomodulatory effects on host responses against methicillin-resistant Staphylococcus aureus biofilms.
    Int J Antimicrob Agents. 2022 Aug 26:106666.
    PubMed     Abstract available

  14. HAJ CE, Benavent E, Sierra Y, Soldevila L, et al
    Comparative efficacy of dalbavancin alone and with rifampicin against in vitro biofilms in a pharmacodynamic model with methicillin-resistant Staphylococcus aureus.
    Int J Antimicrob Agents. 2022 Aug 21:106664.
    PubMed     Abstract available

  15. YEH TK, Lin HJ, Liu PY, Wang JH, et al
    Antibiotic resistance in Enterobacter hormaechei.
    Int J Antimicrob Agents. 2022 Aug 4:106650.
    PubMed     Abstract available

  16. WANG X, Wang Y, Jiang X, Gong X, et al
    Co-transfer of mcr-8 with blaNDM-1 or tmexCD1-toprJ1 by plasmid hybridisation.
    Int J Antimicrob Agents. 2022;60:106619.
    PubMed     Abstract available

  17. TISEO G, Brigante G, Giacobbe DR, Maraolo AE, et al
    Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrob
    Int J Antimicrob Agents. 2022;60:106611.
    PubMed     Abstract available

  18. SACCO F, Raponi G, Oliva A, Bibbolino G, et al
    An outbreak sustained by ST15 Klebsiella pneumoniae carrying 16S rRNA methyltransferases and blaNDM: evaluation of the global dissemination of these resistance determinants.
    Int J Antimicrob Agents. 2022;60:106615.
    PubMed     Abstract available

    June 2022
  19. XIE M, Chen K, Chan EW, Zhang R, et al
    Characterization of clinical carbapenem-resistant K1 Klebsiella quasipneumoniae subsp. similipneumoniae strains harboring virulence plasmid.
    Int J Antimicrob Agents. 2022 Jun 24:106628.
    PubMed     Abstract available

  20. JUAN CH, Chou SH, Chen IR, Yang CI, et al
    Intestinal colonisation with hypervirulent or third-generation cephalosporin-resistant Klebsiella pneumoniae strains upon hospital admission in a general ward in Taiwan.
    Int J Antimicrob Agents. 2022 Jun 18:106624.
    PubMed     Abstract available

  21. JEAN SS, Lee YL, Hsu CW, Hsueh PR, et al
    In vitro susceptibilities of isolates of potentially naturally inducible chromosomal AmpC-producing metallo-beta-lactamase-negative carbapenem-resistant Enterobacterales species to ceftazidime-avibactam: Data from the Antimicrobial Testing Leadership
    Int J Antimicrob Agents. 2022 Jun 16:106617.
    PubMed     Abstract available

  22. BEMER P, Aubry A, Tessier E, d'Epenoux LR, et al
    Emergence of methicillin resistant Staphylococcus epidermidis resistant to linezolid: activity of ceftaroline versus ceftobiprole in a French University French Hospital.
    Int J Antimicrob Agents. 2022 Jun 9:106613.

  23. ZHOU ZL, Tseng KY, Chen YZ, Tsai DJ, et al
    Genetic relatedness among azole-resistant Candida tropicalis clinical strains in Taiwan from 2014 to 2018.
    Int J Antimicrob Agents. 2022;59:106592.
    PubMed     Abstract available

  24. ELIAS R, Spadar A, Phelan J, Melo-Cristino J, et al
    A phylogenomic approach for the analysis of colistin resistance-associated genes in Klebsiella pneumoniae, its mutational diversity and implications for phenotypic resistance.
    Int J Antimicrob Agents. 2022;59:106581.
    PubMed     Abstract available

    May 2022
  25. KIM JH, Kim TS, Chang E, Kang CK, et al
    Effectiveness of antimicrobial stewardship programmes based on rapid antibiotic susceptibility testing of haematologic patients having high-risk factors for bacteraemia related mortality: A post-hoc analysis of an RCT.
    Int J Antimicrob Agents. 2022 May 16:106604.
    PubMed     Abstract available

  26. YU Y, Zhao H, Lin J, Li Z, et al
    Repurposing Non-Antibiotic Drugs Auranofin and Pentamidine in Combination to Combat Multidrug-Resistant Gram-Negative Bacteria.
    Int J Antimicrob Agents. 2022;59:106582.
    PubMed     Abstract available

  27. LIAO W, Cui Y, Quan J, Zhao D, et al
    High prevalence of colistin resistance and mcr-9/10 genes in Enterobacter spp. in a tertiary hospital over a decade.
    Int J Antimicrob Agents. 2022;59:106573.
    PubMed     Abstract available

    April 2022
  28. KOMEDA T, Shrestha S, Sherchan JB, Tohya M, et al
    Emergence of a highly colistin-resistant Aeromonas jandaei clinical isolate harbouring four genes encoding phosphoethanolamine transferases in Nepal.
    Int J Antimicrob Agents. 2022;59:106544.
    PubMed     Abstract available

    March 2022
  29. XU T, Zhou F, Wang L, Wu S, et al
    Metronidazole-Resistant Clostridioides difficile: Genomic and Transcriptomic Traits Acquired under In vitro Metronidazole Induction.
    Int J Antimicrob Agents. 2022 Mar 13:106570.
    PubMed     Abstract available

  30. JOZEFIKOVA A, Valcek A, Soltys K, Novakova E, et al
    Persistence and multi-ward dissemination of vancomycin resistant Enterococcus faecium ST17 clone in hospital settings in Slovakia from 2017 to 2020.
    Int J Antimicrob Agents. 2022 Mar 7:106561.
    PubMed     Abstract available

  31. BALANDIN B, Ballesteros D, Pintado V, Soriano-Cuesta C, et al
    Multicentre study of ceftazidime/avibactam for Gram-negative bacteria infections in critically ill patients.
    Int J Antimicrob Agents. 2022;59:106536.
    PubMed     Abstract available

  32. AHMADI A, Mohammadnejadi E, Karami P, Razzaghi-Asl N, et al
    Current Status and Structure Activity Relationship of Privileged Azoles as Antifungal Agents (2016-2020).
    Int J Antimicrob Agents. 2022;59:106518.
    PubMed     Abstract available

    February 2022
  33. ASLAN AT, Kirbas E, Sancak B, Tanriverdi ES, et al
    A retrospective observational cohort study of the clinical epidemiology of bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae in an OXA-48 endemic setting.
    Int J Antimicrob Agents. 2022 Feb 14:106554.
    PubMed     Abstract available

  34. WANG J, Jiang Y, Ji RY, Wang ZY, et al
    Colistin- and tigecycline-resistant CTX-M-14-producing Salmonella enterica serovar Kentucky ST198 from retail chicken meat, China.
    Int J Antimicrob Agents. 2022;59:106504.

  35. FONSECA EL, Morgado SM, Caldart RV, Freitas F, et al
    Emergence of a VIM-2-producing extensively drug-resistant (XDR) Pseudomonas aeruginosa ST309 in South America: a comparative genomic analysis.
    Int J Antimicrob Agents. 2022;59:106507.
    PubMed     Abstract available

  36. NANG SC, Li M, Harper M, Mandela E, et al
    Polymyxin causes cell envelope remodelling and stress responses in mcr-1-harbouring Escherichia coli.
    Int J Antimicrob Agents. 2022;59:106505.
    PubMed     Abstract available

  37. GUZMAN-PUCHE J, Perez-Nadales E, Perez-Vazquez M, Causse M, et al
    In vivo selection of KPC-94 and KPC-95 in Klebsiella pneumoniae isolates from patients treated with ceftazidime/avibactam.
    Int J Antimicrob Agents. 2022;59:106524.
    PubMed     Abstract available

    January 2022
  38. HUANG YC, Chen CJ
    USA 300 (sequence type 8) became a major clone of methicillin-resistant Staphylococcus aureus in northern Taiwan.
    Int J Antimicrob Agents. 2022 Jan 25:106534.
    PubMed     Abstract available

  39. DOBBYN D, Zeggil T, Kudrowich B, Beahm NP, et al
    Ciprofloxacin Resistances Rates in Escherichia coli Across Canada (CREAC): A Longitudinal Analysis 2015-2019.
    Int J Antimicrob Agents. 2022 Jan 25:106532.
    PubMed     Abstract available

  40. WANG WY, Hsueh PR, Tsao SM
    Genotyping of methicillin-resistant Staphylococcus aureus isolates causing invasive infections using spa typing and their correlation with antibiotic susceptibility.
    Int J Antimicrob Agents. 2022 Jan 15:106525.
    PubMed     Abstract available

  41. ARMENIA D, Santoro MM, Bellocchi MC, Carioti L, et al
    Viral resistance burden and APOBEC editing correlate with virological response in heavily treatment-experienced people living with multi-drug resistant HIV.
    Int J Antimicrob Agents. 2022;59:106492.
    PubMed     Abstract available

  42. PAN Y, Zeng Z, Niu H, Huang L, et al
    Whole-genome epidemiology and characterisation of mcr-1-encoding Escherichia coli in aquatic bird farms from the Pearl River Delta, China, 2019-2020.
    Int J Antimicrob Agents. 2022;59:106478.
    PubMed     Abstract available

  43. KAWAMOTO Y, Kaku N, Akamatsu N, Sakamoto K, et al
    The surveillance of colistin resistance and mobilized colistin resistance genes in multidrug-resistant Enterobacteriaceae isolated in Japan.
    Int J Antimicrob Agents. 2022;59:106480.
    PubMed     Abstract available

  44. YEH TK, Jean SS, Lee YL, Lu MC, et al
    Bacteriophages and phage-delivered CRISPR-Cas system as antibacterial therapy.
    Int J Antimicrob Agents. 2022;59:106475.
    PubMed     Abstract available

  45. LUO YC, Hsieh YC, Wu JW, Quyen TLT, et al
    Exploring the association between capsular types, sequence types, and carbapenemase genes in Acinetobacter baumannii.
    Int J Antimicrob Agents. 2022;59:106470.
    PubMed     Abstract available

  46. ARCA-SUAREZ J, Rodino-Janeiro BK, Perez A, Guijarro-Sanchez P, et al
    Emergence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacterales in Spain studied by whole-genome sequencing.
    Int J Antimicrob Agents. 2022;59:106456.
    PubMed     Abstract available

    December 2021
  47. LEE SS, Cheng KF, Wong NS, Kwan CK, et al
    The emergence of antibiotic resistant Mycoplasma genitalium as the cause of non-gonococcal urethritis in male sexually transmitted infection clinic patients.
    Int J Antimicrob Agents. 2021 Dec 28:106510.
    PubMed     Abstract available

  48. WEI L, Feng Y, Wen H, Ya H, et al
    NDM-5-producing carbapenem-resistant Klebsiella pneumoniae of sequence type 789 emerged as a threat for neonates: a multi-center genome-based study.
    Int J Antimicrob Agents. 2021 Dec 24:106508.
    PubMed     Abstract available

  49. GARZA M, Mohan CV, Brunton L, Wieland B, et al
    Typology of interventions for antimicrobial use and antimicrobial resistance in aquaculture systems in LMICs.
    Int J Antimicrob Agents. 2021 Dec 9:106495.
    PubMed     Abstract available

  50. WESTERHOLT M, Hasman H, Hansen DS, Roer L, et al
    Screening patients at admission to Copenhagen hospitals for carriage of resistant bacteria after contact with healthcare systems abroad, 2016-2019.
    Int J Antimicrob Agents. 2021;58:106452.
    PubMed     Abstract available

  51. KIM JS, Yu JK, Jeon SJ, Park SH, et al
    Dissemination of an international high-risk clone of Escherichia coli ST410 co-producing NDM-5 and OXA-181 carbapenemases in Seoul, Republic of Korea.
    Int J Antimicrob Agents. 2021;58:106448.
    PubMed     Abstract available

  52. RECIO R, Viedma E, Gonzalez-Bodi S, Villa J, et al
    Clinical and bacterial characteristics of Pseudomonas aeruginosa affecting the outcome of patients with bacteraemic pneumonia.
    Int J Antimicrob Agents. 2021;58:106450.
    PubMed     Abstract available

  53. YOSHIKAWA Y, Feldhaus I, Ozcelik E, Hashiguchi TCO, et al
    Financial strategies targeting healthcare providers to promote the prudent use of antibiotics: a systematic review of the evidence.
    Int J Antimicrob Agents. 2021;58:106446.
    PubMed     Abstract available

    November 2021
  54. SEIFERT H, von Linstow ML, Janssen H, Dowzicky M, et al
    Antimicrobial Susceptibility among Gram-Negative Isolates in Pediatric Patients in Europe from 2013-2018 Compared to 2004-2012: Results from the ATLAS Surveillance Study.
    Int J Antimicrob Agents. 2021;58:106441.
    PubMed     Abstract available

  55. CEBRIAN R, Xu C, Xia Y, Wu W, et al
    The cathelicidin-derived close-to-nature peptide D-11 sensitises Klebsiella pneumoniae to a range of antibiotics in vitro, ex vivo and in vivo.
    Int J Antimicrob Agents. 2021;58:106434.
    PubMed     Abstract available

  56. ZHU C, Li C, Lai CKC, Ng R, et al
    Longitudinal Genomic Characterization of Carbapenemase-producing Enterobacteriaceae (CPE) Reveals Changing Pattern of CPE Isolated in Hong Kong Hospitals.
    Int J Antimicrob Agents. 2021;58:106430.
    PubMed     Abstract available

  57. GIUFRE M, Mazzolini E, Cerquetti M, Brusaferro S, et al
    Extended-spectrum beta-lactamase-producing Escherichia coli from extraintestinal infections in humans and from food-producing animals in Italy: a 'One Health' study.
    Int J Antimicrob Agents. 2021;58:106433.
    PubMed     Abstract available

  58. RODRIGUEZ-SANTIAGO J, Cornejo-Juarez P, Silva-Sanchez J, Garza-Ramos U, et al
    Polymyxin resistance in Enterobacterales: overview and epidemiology in the Americas.
    Int J Antimicrob Agents. 2021;58:106426.
    PubMed     Abstract available

  59. LENZI MH, Martins WM, Roch M, Ramos PL, et al
    A new mutation in mgrb mediating polymyxin resistance in Klebsiella variicola.
    Int J Antimicrob Agents. 2021;58:106424.
    PubMed     Abstract available

    October 2021
  60. BOAS DO PRADO GV, Mendes ET, Martins RCR, Perdigao-Neto LV, et al
    Phenotypic and genotypic characteristics of a Carbapenem-resistant Serratia marcescens cohort and outbreak: describing an opportunistic pathogen.
    Int J Antimicrob Agents. 2021 Oct 26:106463.
    PubMed     Abstract available

  61. UDE Z, Flothkotter N, Sheehan G, Brennan M, et al
    Multi-Targeted Metallo-Ciprofloxacin Derivatives Rationally Designed and Developed to Overcome Antimicrobial Resistance.
    Int J Antimicrob Agents. 2021 Oct 10:106449.
    PubMed     Abstract available

  62. CHEN T, Fu Y, Hua X, Xu Q, et al
    Acinetobacter baumannii strains isolated from cerebrospinal fluid (CSF) and bloodstream analysed by cgMLST: the dominance of clonal complex CC92 in CSF infections.
    Int J Antimicrob Agents. 2021;58:106404.
    PubMed     Abstract available

  63. MILTGEN G, Bour M, Allyn J, Allou N, et al
    Molecular and epidemiological investigation of a colistin-resistant OXA-23-/NDM-1-producing Acinetobacter baumannii outbreak in the Southwest Indian Ocean Area.
    Int J Antimicrob Agents. 2021;58:106402.
    PubMed     Abstract available

  64. SALVATO RS, Reis AJ, Schiefelbein SH, Gomez MAA, et al
    Genomic-based surveillance reveals high ongoing transmission of multi-drug-resistant Mycobacterium tuberculosis in Southern Brazil.
    Int J Antimicrob Agents. 2021;58:106401.
    PubMed     Abstract available

    September 2021
  65. MAGALLON J, Vu P, Reeves C, Kwan S, et al
    Amikacin in combination with zinc pyrithione prevents growth of a carbapenem-resistant/multidrug-resistant Klebsiella pneumoniae isolate.
    Int J Antimicrob Agents. 2021 Sep 19:106442.

  66. CASTANHEIRA M, Doyle TB, Deshpande LM, Mendes RE, et al
    Activity of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem-Relebactam against Carbapenemase-negative Carbapenem-resistant Enterobacterales (CRE) isolates from US Hospitals.
    Int J Antimicrob Agents. 2021 Sep 18:106439.
    PubMed     Abstract available

  67. RUSSO A, Venditti M
    Vertebral osteomyelitis caused by vancomycin-resistant Enterococcus spp: a case series.
    Int J Antimicrob Agents. 2021 Sep 12:106432.

  68. FOLETTO VS, da Rosa TF, Serafin MB, Bottega A, et al
    Repositioning of non-antibiotic drugs as an alternative to microbial resistance: a systematic review.
    Int J Antimicrob Agents. 2021;58:106380.
    PubMed     Abstract available

  69. MULDER M, Arp PP, Kiefte-de Jong JC, Uitterlinden AG, et al
    Prevalence of and risk factors for extended-spectrum beta-lactamase genes carriership in a population-based cohort of middle-aged and elderly.
    Int J Antimicrob Agents. 2021;58:106388.
    PubMed     Abstract available

  70. MORENO-MINGORANCE A, Espinal P, Rodriguez V, Goterris L, et al
    Circulation of multi-drug-resistant Shigella sonnei and Shigella flexneri among men who have sex with men in Barcelona, Spain, 2015-2019.
    Int J Antimicrob Agents. 2021;58:106378.
    PubMed     Abstract available

  71. FRATONI AJ, Kuti JL, Nicolau DP
    Optimised cefiderocol exposures in a successfully treated critically ill patient with polymicrobial Stenotrophomonas maltophilia bacteraemia and pneumonia receiving continuous venovenous haemodiafiltration.
    Int J Antimicrob Agents. 2021;58:106395.

  72. FUENTES-CASTILLO D, Shiva C, Lincopan N, Sano E, et al
    Global high-risk clone of extended-spectrum beta-lactamase (ESBL)-producing Klebsiella pneumoniae ST307 emerging in livestock in Peru.
    Int J Antimicrob Agents. 2021;58:106389.

    August 2021
  73. KIM JS, Yu JK, Jeon SJ, Park SH, et al
    Distribution of mcr genes among carbapenem-resistant Enterobacterales clinical isolates: High prevalence of mcr-positive Enterobacter cloacae complex in Seoul, Republic of Korea.
    Int J Antimicrob Agents. 2021 Aug 12:106418.
    PubMed     Abstract available

  74. ALLEN GP, Deao KM, Hill SA, Schipelliti SM, et al
    In vitro evaluation of antimicrobial resistance selection in Neisseria gonorrhoeae.
    Int J Antimicrob Agents. 2021 Aug 12:106417.
    PubMed     Abstract available

  75. IWU CD, Patrick SM
    An insight into the Implementation of the Global Action Plan on Antimicrobial Resistance in the WHO African Region: A Roadmap for Action.
    Int J Antimicrob Agents. 2021 Aug 6:106411.
    PubMed     Abstract available

  76. LU S, Li D, Wang L, Bi Y, et al
    Promoter variations associated with expression of mcr-1 gene and level of colistin resistance.
    Int J Antimicrob Agents. 2021;58:106371.
    PubMed     Abstract available

  77. LI J, Roberts J
    Antibiotic pharmacokinetics/pharmacodynamics: where are we heading?
    Int J Antimicrob Agents. 2021;58:106369.

  78. JUNCO SJ, Bowman MC, Turner RB
    Clinical outcomes of Stenotrophomonas maltophilia infection treated with trimethoprim/sulfamethoxazole, minocycline, or fluoroquinolone monotherapy.
    Int J Antimicrob Agents. 2021;58:106367.
    PubMed     Abstract available

  79. RAO GG, Landersdorfer CB
    Antibiotic pharmacokinetic/pharmacodynamic modelling: MIC, pharmacodynamic indices and beyond.
    Int J Antimicrob Agents. 2021;58:106368.
    PubMed     Abstract available

    July 2021
  80. WARETH G, Linde J, Hammer P, Nguyen NH, et al
    Corrigendum to "Phenotypic and WGS-derived antimicrobial resistance profiles of clinical and non-clinical Acinetobacter baumannii isolates from Germany and Vietnam" [International Journal of Antimicrobial Agents, Volume 56, Issue 4, October 2020, 1061
    Int J Antimicrob Agents. 2021 Jul 26:106407.

  81. RAMBLIERE L, Guillemot D, Delarocque-Astagneau E, Huynh BT, et al
    Erratum to "Impact of mass and systematic antibiotic administration on antibiotic resistance in low- and middle-income countries. A systematic review" [International Journal of Antimicrobial Agents (2021) Volume 58, Issue 1/106364].
    Int J Antimicrob Agents. 2021 Jul 14:106396.

  82. ANTONELLO RM, Di Bella S, Betts J, La Ragione R, et al
    Zidovudine in synergistic combination with fosfomycin: an in vitro and in vivo evaluation against multidrug-resistant Enterobacterales.
    Int J Antimicrob Agents. 2021;58:106362.
    PubMed     Abstract available

  83. LAI CC, Yu WL
    Klebsiella pneumoniae Harboring Carbapenemase Genes in Taiwan: Its Evolution over 20 Years, 1998-2019.
    Int J Antimicrob Agents. 2021;58:106354.
    PubMed     Abstract available

    June 2021
  84. LEE YL, Ko WC, Lee WS, Lu PL, et al
    In vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline, and other comparative agents against carbapenem-nonsusceptible Enterobacterales: Results from the Surveillance of Multicenter Antimicrobial Res
    Int J Antimicrob Agents. 2021 Jun 21:106377.
    PubMed     Abstract available

  85. CHAIYACHAT P, Chaiprasert A, Nonghanphithak D, Smithtikarn S, et al
    Whole-genome analysis of drug-resistant Mycobacterium tuberculosis reveals novel mutations associated with fluoroquinolone resistance.
    Int J Antimicrob Agents. 2021 Jun 20:106385.
    PubMed     Abstract available

  86. MOOR J, Aebi S, Rickli S, Mostacci N, et al
    Dynamics of extended-spectrum cephalosporin-resistant E. coli in pig farms: A longitudinal study.
    Int J Antimicrob Agents. 2021 Jun 19:106382.
    PubMed     Abstract available

  87. TIMMERMANS M, Wattiau P, Denis O, Boland C, et al
    Colistin resistance genes mcr-1 to mcr-5, including a case of triple occurrence (mcr-1, -3 and -5), in Escherichia coli isolates from faeces of healthy pigs, cattle and poultry in Belgium, 2012-2016.
    Int J Antimicrob Agents. 2021;57:106350.
    PubMed     Abstract available

  88. CLERICI D, Oltolini C, Greco R, Ripa M, et al
    The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia.
    Int J Antimicrob Agents. 2021;57:106335.
    PubMed     Abstract available

  89. ALMANGOUR TA, Garcia E, Zhou Q, Forrest A, et al
    Polymyxins for the treatment of lower respiratory tract infections: lessons learned from the integration of clinical pharmacokinetic studies and clinical outcomes.
    Int J Antimicrob Agents. 2021;57:106328.
    PubMed     Abstract available

    May 2021
  90. RAMBLIERE L, Guillemot D, Delarocque-Astagneau E, Huynh BT, et al
    What is the impact of mass and systematic antibiotic administration on antibiotic resistance in low- and middle-income countries? A systematic review: AR after mass/systematic antibiotic administration.
    Int J Antimicrob Agents. 2021 May 24:106364.
    PubMed     Abstract available

  91. DELORY T, Gravier S, Pluart DL, Gaube G, et al
    Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study.
    Int J Antimicrob Agents. 2021 May 14:106361.
    PubMed     Abstract available

  92. TSAI HY, Lee YL, Liu PY, Lu MC, et al
    Antimicrobial susceptibility of bacteremic vancomycin-resistant Enterococcus faecium to eravacycline, omadacycline, lipoglycopeptides, and other comparator antibiotics: Results from the 2019/2020 Nationwide Surveillance of Multicenter Antimicrobial Re
    Int J Antimicrob Agents. 2021 May 4:106353.
    PubMed     Abstract available

  93. MEI CY, Wu H, Wang Y, Wang ZY, et al
    First detection of the multiresistance gene cfr in Escherichia coli from retail vegetables, China.
    Int J Antimicrob Agents. 2021;57:106348.

  94. MBHELE N, Chimukangara B, Gordon M
    HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance.
    Int J Antimicrob Agents. 2021;57:106343.
    PubMed     Abstract available

  95. WANG X, Ling Z, Sun N, Liu Y, et al
    Molecular genetic characteristics of mcr-9-harbouring Salmonella enterica serotype Typhimurium isolated from raw milk.
    Int J Antimicrob Agents. 2021;57:106332.
    PubMed     Abstract available

  96. NGUYEN HT, Venter H, Veltman T, Williams R, et al
    In vitro synergistic activity of NCL195 in combination with colistin against Gram-negative bacterial pathogens.
    Int J Antimicrob Agents. 2021;57:106323.
    PubMed     Abstract available

  97. MUSHTAQ S, Garello P, Vickers A, Woodford N, et al
    Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria.
    Int J Antimicrob Agents. 2021;57:106318.
    PubMed     Abstract available

    April 2021
  98. KOSTYANEV T, Xavier BB, Garcia-Castillo M, Lammens C, et al
    Phenotypic and Molecular Characterisations of Carbapenem-resistant Acinetobacter baumannii Isolates Collected within the EURECA Study.
    Int J Antimicrob Agents. 2021 Apr 19:106345.
    PubMed     Abstract available

  99. HUANG PH, Cheng YH, Chen WY, Juan CH, et al
    Risk factors and mechanisms of in vivo emergence of colistin resistance in carbapenem-resistant Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2021 Apr 14:106342.
    PubMed     Abstract available

  100. CREMET L, Leroy AG, Muller D, Delanou S, et al
    Antibiotic Resistance Heterogeneity and LasR Diversity within Pseudomonas aeruginosa Populations from Pneumonia in Intensive Care Unit Patients.
    Int J Antimicrob Agents. 2021 Apr 12:106341.
    PubMed     Abstract available

  101. SCUDELLER L, Righi E, Chiamenti M, Bragantini D, et al
    Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
    Int J Antimicrob Agents. 2021 Apr 12:106344.
    PubMed     Abstract available

  102. TANG SSL, Chee E, Teo JQ, Chlebicki MP, et al
    Incidence of a subsequent carbapenem-resistant Enterobacteriaceae infection after previous colonisation or infection: a prospective cohort study.
    Int J Antimicrob Agents. 2021 Apr 12:106340.
    PubMed     Abstract available

  103. KLEIN S, Boutin S, Heeg K, Zanger P, et al
    Genomic structure of ST8-t008 USA300 and USA300-LV MRSA in the Rhine-Neckar Region, Germany, 2012-2018.
    Int J Antimicrob Agents. 2021;57:106312.
    PubMed     Abstract available

  104. HERRERA M, Gregorio SD, Haim MS, Posse G, et al
    Genetic changes associated with tigecycline resistance in Staphylococcus aureus in vitro-selected mutants belonging to different lineages.
    Int J Antimicrob Agents. 2021;57:106304.
    PubMed     Abstract available

    March 2021
  105. BONNIN RA, Girlich D, Jousset AB, Emeraud C, et al
    Genomic analysis of VIM-2-producing Enterobacter hormaechei subsp. steigerwaltii.
    Int J Antimicrob Agents. 2021;57:106285.
    PubMed     Abstract available

  106. NI M, Zhao L, Zhang WJ, Ma JW, et al
    Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration alone in intracranial infections.
    Int J Antimicrob Agents. 2021;57:106281.
    PubMed     Abstract available

  107. JOHNSON MG, Bruno C, Castanheira M, Yu B, et al
    Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).
    Int J Antimicrob Agents. 2021;57:106278.
    PubMed     Abstract available

  108. VAN BILSEN WPH, van Dulm E, Matser A, Linde I, et al
    High carriage of ESBL-producing Enterobacteriaceae associated with sexual activity among men who have sex with men.
    Int J Antimicrob Agents. 2021;57:106276.
    PubMed     Abstract available

  109. BALANDIN B, Ballesteros D, Ruiz de Luna R, Lopez-Vergara L, et al
    Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients.
    Int J Antimicrob Agents. 2021;57:106270.
    PubMed     Abstract available

  110. CIMOLAI N
    Pharmacotherapy for Bordetella pertussis infection. II. A synthesis of clinical sciences.
    Int J Antimicrob Agents. 2021;57:106257.
    PubMed     Abstract available

  111. CIMOLAI N
    Pharmacotherapy for Bordetella pertussis infection. I. A synthesis of laboratory sciences.
    Int J Antimicrob Agents. 2021;57:106258.
    PubMed     Abstract available

    February 2021
  112. HERNANDEZ-GARCIA M, Garcia-Fernandez S, Garcia-Castillo M, Melo-Cristino J, et al
    Confronting Ceftolozane-Tazobactam Susceptibility in Multidrug-Resistant Enterobacterales Isolates and Whole-Genome Sequencing Results (STEP Study).
    Int J Antimicrob Agents. 2021;57:106259.
    PubMed     Abstract available

  113. CHERNOVA OA, Chernov VM, Mouzykantov AA, Baranova NB, et al
    Antimicrobial drug resistance mechanisms among Mollicutes.
    Int J Antimicrob Agents. 2021;57:106253.
    PubMed     Abstract available

  114. XU Q, Sheng Z, Hao M, Jiang J, et al
    RamA upregulates multidrug resistance efflux pumps AcrAB and OqxAB in Klebsiella pneumoniae.
    Int J Antimicrob Agents. 2021;57:106251.
    PubMed     Abstract available

  115. LOMBARDI F, Giacomelli A, Armenia D, Lai A, et al
    Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database.
    Int J Antimicrob Agents. 2021;57:106252.
    PubMed     Abstract available

  116. GOMEZ-JUNYENT J, Murillo O, Yu HH, Azad MAK, et al
    In vitro pharmacokinetics/pharmacodynamics of continuous ceftazidime infusion alone and in combination with colistin against Pseudomonas aeruginosa biofilm.
    Int J Antimicrob Agents. 2021;57:106246.
    PubMed     Abstract available

    January 2021
  117. PICCIRILLI A, Segatore B, Brisdelli F, Amicosante G, et al
    Potent inhibitory activity of taniborbactam towards NDM-1 and NDM-1(Q119X) mutants, and in vitro activity of cefepime/taniborbactam against MBLs producing Enterobacterales.
    Int J Antimicrob Agents. 2021;57:106228.
    PubMed     Abstract available

  118. HUANG L, Cao M, Hu Y, Zhang R, et al
    Prevalence and mechanisms of fosfomycin resistance among KPC-producing Klebsiella pneumoniae clinical isolates in China.
    Int J Antimicrob Agents. 2021;57:106226.
    PubMed     Abstract available

  119. FREITAS AR, Pereira AP, Novais C, Peixe L, et al
    Multidrug-resistant high-risk Enterococcus faecium clones: can we really define them?
    Int J Antimicrob Agents. 2021;57:106227.
    PubMed     Abstract available

  120. OUCHAR MAHAMAT O, Kempf M, Lounnas M, Tidjani A, et al
    Epidemiology and prevalence of extended-spectrum beta-lactamase- and carbapenemase-producing Enterobacteriaceae in humans, animals and the environment in West and Central Africa.
    Int J Antimicrob Agents. 2021;57:106203.
    PubMed     Abstract available

    August 2020
  121. IANNACCONE M, Boattini M, Bianco G, Cavallo R, et al
    Meropenem/vaborbactam-based combinations against KPC-producing Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa.
    Int J Antimicrob Agents. 2020;56:106066.

  122. ANDRE-GARNIER E, Hingrat QL, Marcelin AG, Reliquet V, et al
    Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure.
    Int J Antimicrob Agents. 2020;56:106039.

    July 2020
  123. MOWLABOCCUS S, Daley D, Pang S, Gottlieb T, et al
    Identification and Characterisation of Fosfomycin Resistance in Escherichia coli Urinary Tract Infection Isolates from Australia.
    Int J Antimicrob Agents. 2020 Jul 30:106121.
    PubMed     Abstract available

  124. NGUYEN HM, Graber CJ
    A Critical Review of Cephalexin and Cefadroxil for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection in the Era of "Bad Bugs, Few Drugs".
    Int J Antimicrob Agents. 2020 Jul 10:106085.
    PubMed     Abstract available

  125. MARTINS WMBS, Seco BMS, Sampaio JLM, Sands K, et al
    Detection of BKC-1 in Citrobacter freundii: A clue to mobilisation in an IncQ1 plasmid carrying blaBKC-1.
    Int J Antimicrob Agents. 2020;56:106042.

  126. HSU CY, Chen FJ, Huang WC, Liao YC, et al
    Plasmid- and chromosome-located mcr-3 in mcr-1-positive Escherichia coli in Taiwan.
    Int J Antimicrob Agents. 2020;56:105996.

  127. FURLAN JPR, Savazzi EA, Stehling EG
    Widespread high-risk clones of multidrug-resistant extended-spectrum beta-lactamase-producing Escherichia coli B2-ST131 and F-ST648 in public aquatic environments.
    Int J Antimicrob Agents. 2020;56:106040.
    PubMed     Abstract available

  128. PEREZ-VAZQUEZ M, Sola-Campoy PJ, Zurita AM, Avila A, et al
    Carbapenemase-producing Pseudomonas aeruginosa in Spain: interregional dissemination of the high-risk clones ST175 and ST244 carrying blaVIM-2, blaVIM-1, blaIMP-8, blaVIM-20 and blaKPC-2.
    Int J Antimicrob Agents. 2020;56:106026.
    PubMed     Abstract available

  129. SANTORO MM, Fornabaio C, Malena M, Galli L, et al
    Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
    Int J Antimicrob Agents. 2020;56:106027.
    PubMed     Abstract available

  130. GAURAV A, Kothari A, Omar BJ, Pathania R, et al
    Assessment of polymyxin B-doxycycline in combination against Pseudomonas aeruginosa in vitro and in a mouse model of acute pneumonia.
    Int J Antimicrob Agents. 2020;56:106022.
    PubMed     Abstract available

  131. BARBOSA F, Pinto E, Kijjoa A, Pinto M, et al
    Targeting antimicrobial drug resistance with marine natural products.
    Int J Antimicrob Agents. 2020;56:106005.
    PubMed     Abstract available

  132. WILLCOCKS SJ, Cia F, Francisco AF, Wren BW, et al
    Revisiting aminocoumarins for the treatment of melioidosis.
    Int J Antimicrob Agents. 2020;56:106002.
    PubMed     Abstract available

  133. CHEN L, Han D, Tang Z, Hao J, et al
    Co-existence of the oxazolidinone resistance genes cfr and optrA on two transferable multi-resistance plasmids in one Enterococcus faecalis isolate from swine.
    Int J Antimicrob Agents. 2020;56:105993.
    PubMed     Abstract available

  134. KAVANAUGH LG, Flanagan JN, Steck TR
    Reciprocal antibiotic collateral sensitivity in Burkholderia multivorans.
    Int J Antimicrob Agents. 2020;56:105994.
    PubMed     Abstract available

  135. DOGAN O, Yesilkaya A, Menekse S, Guler O, et al
    Effect of initial antifungal therapy on mortality among patients with bloodstream infections with different Candida species and resistance to antifungal agents: A multicentre observational study by the Turkish Fungal Infections Study Group.
    Int J Antimicrob Agents. 2020;56:105992.
    PubMed     Abstract available

  136. NOEL A, Attwood M, Bowker K, MacGowan A, et al
    The pharmacodynamics of fosfomycin against Staphylococcus aureus studied in an in vitro model of infection.
    Int J Antimicrob Agents. 2020;56:105985.
    PubMed     Abstract available

  137. STRAZZULLA A, Iordache L, de Pontfarcy A, Pitsch A, et al
    beta-Lactam allergy and risk of multidrug-resistant bacteria in the intensive care unit: A cohort study.
    Int J Antimicrob Agents. 2020;56:105979.
    PubMed     Abstract available

  138. CAI T, Tamanini I, Mattevi D, Verze P, et al
    Fosfomycin trometamol and N-acetyl-L-cysteine as combined oral therapy of difficult-to-treat chronic bacterial prostatitis: Results of a pilot study.
    Int J Antimicrob Agents. 2020;56:105935.
    PubMed     Abstract available

  139. PERALES C
    Quasispecies dynamics and clinical significance of hepatitis C virus (HCV) antiviral resistance.
    Int J Antimicrob Agents. 2020;56:105562.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Drug Resistance is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.